In a late-night address on Christmas, PM Modi announced that those aged between 15-18 years of age will now be eligible for vaccinations from 3 January. “Precautionary doses” of a COVID vaccine will also be administered to frontline workers and those who are 60 years and above with comorbidities will be administered doses from 10 January.
Though the decision to expand vaccination coverage has been widely welcomed, four critical questions regarding them have emerged:
First, why call it a precautionary dose and not a booster dose? Does this signal that the third shot will be Covishield or Covaxin? This leads us to the second question, how effective is a third dose of the same vaccine?
Third, given that Covaxin is the only vaccine in production to be cleared for inoculating those under 18, is it worrying that there is no publicly available data of the trials? And lastly, will the restriction on additional doses for those over the age of 60 cause problems?
Guests:
Dr Chandrakand Lahairya, an epidemiologist and health systems expert.
Dr Rakesh Mishra, former director of the Center for Cellular and Molecular Biology.
Host and Producer: Himmat Shaligram Editor: Eshwar Ranjana
Music: Big Bang Fuzz
Listen to The Big Story podcast on:
Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur